- Home
- ALV vs LEGN Comparison
ALV vs LEGN Comparison
Compare ALV & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALV | LEGN |
|---|---|---|
| Founded | 1953 | 2014 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 5.9B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALV | LEGN |
|---|---|---|
| Price | $119.65 | $21.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $133.45 | $69.67 |
| AVG Volume (30 Days) | 568.2K | ★ 2.7M |
| Earning Date | 01-30-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | ★ 25.57 | N/A |
| EPS | ★ 9.69 | N/A |
| Revenue | ★ $10,614,000,000.00 | $909,045,000.00 |
| Revenue This Year | $4.73 | $68.83 |
| Revenue Next Year | $4.40 | $51.27 |
| P/E Ratio | $12.42 | ★ N/A |
| Revenue Growth | 0.85 | ★ 74.75 |
| 52 Week Low | $75.49 | $21.51 |
| 52 Week High | $129.54 | $45.30 |
Technical Indicators
Market Signals| Indicator | ALV | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.91 | 20.03 |
| Support Level | $115.99 | $26.43 |
| Resistance Level | $122.90 | $28.97 |
| Average True Range (ATR) | 2.27 | 1.25 |
| MACD | 0.36 | -0.41 |
| Stochastic Oscillator | 54.81 | 0.73 |
Price Performance
Historical ComparisonAbout ALV Autoliv Inc.
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.